Bengaluru – Biocon Biologics, the biopharmaceutical arm of Biocon Ltd, is strengthening its foothold in the global insulin market while making a decisive move into the booming GLP-1 drug segment. The company expects its generic version of semaglutide — a breakthrough treatment for diabetes and weight management — to hit the market in 2027.
Shreehas Tambe, CEO and Managing Director of http://Biocon BiologicsBiocon Biologics, told Medicare News that decades of experience in insulin production will give Biocon an edge as it enters the competitive GLP-1 space. “The disruption from GLP-1 drugs is complementary to insulin. We are bullish on both,” Tambe said.
Semaglutide Launch Plans
Biocon has completed bioequivalence studies in India for semaglutide and is progressing to Phase-III trials, expected to wrap up by the end of 2026. Regulatory approval is targeted for 2027, after which the company plans a commercial launch with a strategic partner.
Novo Nordisk’s blockbuster semaglutide, sold under brands like Wegovy, will lose its Indian patent in March. This is expected to open doors for biosimilar competition in one of the fastest-growing therapeutic categories.
Synergy Between Insulin and GLP-1 Therapies
Tambe noted that leading insulin companies were the first to bring GLP-1 products to market, leveraging synergies in therapy, operations, and patient care. “Both are chronic treatments, delivered via devices, requiring a long-term relationship with patients and ongoing training,” he explained.
Biocon’s global insulin experience — with products available in over 80 countries — will now extend to GLP-1 peptides, which mimic a natural gut hormone that regulates blood sugar and appetite.
US Market Strength
The company recently secured US Food and Drug Administration (FDA) approval for Kirsty, its biosimilar insulin aspart. This is Biocon’s second interchangeable biosimilar insulin after Semglee (insulin glargine). The dual offering allows Biocon to provide both short-acting and long-acting affordable insulin options in the US market, deepening its presence and competitiveness.
“The US FDA approval builds on our strong foundation in biosimilar insulins. It positions us to serve patients with a full range of insulin therapies at affordable prices,” Tambe said.
Operational Expertise as a Differentiator
Biocon’s strength lies in its expertise with injectable devices, cold chain logistics, regulatory compliance, and physician engagement. These operational competencies are critical in markets where patient adherence and device handling are essential to therapeutic success.
Industry analysts believe that by combining insulin and GLP-1 portfolios, Biocon can tap into complementary revenue streams and enhance its long-term growth trajectory. With the global GLP-1 market projected to cross $100 billion by 2030, Biocon’s timely entry could be a game-changer.
